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1Prediction of ESRD and Death Among People With CKD: The Chronic
Renal Impairment in Birmingham (CRIB) Prospective Cohort Study
Martin J. Landray, PhD, FRCP,1 Jonathan R. Emberson, PhD,1 Lisa Blackwell, BSc,1
Tanaji Dasgupta, MRCP,1 Rosita Zakeri, MRCP,2 Matthew D. Morgan, MRCP, PhD,3
Charlie J. Ferro, BSc, MD, FRCP,2 Susan Vickery, MSc, PhD,4
Puja Ayrton, MSc, MRCP, MRCPath,5 Devaki Nair, MSc, FRCPath,6 R. Neil Dalton, MA, PhD,7
Edmund J. Lamb, PhD, FRCPath,4 Colin Baigent, MSc, FRCP,1
Jonathan N. Townend, MD, FRCP,2 and David C. Wheeler, MD, FRCP8
Background: Validated prediction scores are required to assess the risks of end-stage renal disease
(ESRD) and death in individuals with chronic kidney disease (CKD).
Study Design: Prospective cohort study with validation in a separate cohort.
Setting & Participants: Cox regression was used to assess the relevance of baseline characteristics
to risk of ESRD (mean follow-up, 4.1 years) and death (mean follow-up, 6.0 years) in 382 patients with
stages 3-5 CKD not initially on dialysis therapy in the Chronic Renal Impairment in Birmingham (CRIB)
Study. Resultant risk prediction equations were tested in a separate cohort of 213 patients with CKD (the
East Kent cohort).
Factors: 44 baseline characteristics (including 30 blood and urine assays).
Outcomes: ESRD and all-cause mortality.
Results: In the CRIB cohort, 190 patients reached ESRD (12.1%/y) and 150 died (6.5%/y). Each 30%
lower baseline estimated glomerular filtration rate was associated with a 3-fold higher ESRD rate and a
1.3-fold higher death rate. After adjustment for each other, only baseline creatinine level, serum
phosphate level, urinary albumin-creatinine ratio, and female sex remained strongly (P  0.01)
predictive of ESRD. For death, age, N-terminal pro-brain natriuretic peptide, troponin T level, and
cigarette smoking remained strongly predictive of risk. Using these factors to predict outcomes in the
East Kent cohort yielded an area under the receiver operating characteristic curve (ie, C statistic) of 0.91
(95% CI, 0.87-0.96) for ESRD and 0.82 (95% CI, 0.75-0.89) for death.
Limitations: Other important factors may have been missed because of limited study power.
Conclusions: Simple laboratory measures of kidney and cardiac function plus age, sex, and smoking
history can be used to help identify patients with CKD at highest risk of ESRD and death. Larger cohort
studies are required to further validate these results.
Am J Kidney Dis 56:1082-1094. © 2010 by the National Kidney Foundation, Inc.
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un Western populations, approximately 5%-
10% of the adult population have an esti-
ated glomerular filtration rate (eGFR) 60
L/min/1.73 m2 (ie, chronic kidney disease
CKD] stages 3-5).1-3 These individuals are at
ncreased risk of death (particularly from cardio-
ascular causes) and progression to end-stage
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American Journal of Kidney082enal disease (ESRD; ie, the need for dialysis or
idney transplant) compared with those without
KD.4,5 Decreased kidney function is associated
ith many factors that might be associated with
ncreased risks of death, ESRD, or both.6-11
owever, for a particular patient with CKD, it is
nclear how knowledge of phenotypic factors
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Risk of ESRD and Death in CKD 1083an be used to determine the likelihood of requir-
ng renal replacement therapy or of dying within
he next few years.12 In particular, risk equations
eveloped in the general population (such as
hose derived for cardiovascular death from the
ramingham study)13 are not accurate in patients
ith CKD because the relationships between
lassic risk markers (such as cholesterol level or
lood pressure) and adverse outcomes are weak
nd can even be reversed because of extensive
onfounding by both disease and treatment.14
This study aims to quantify and compare the
isks of death and ESRD in a cohort of patients
ith CKD stages 3-5 (but not receiving renal
eplacement therapy) and develop clinically use-
ul methods for predicting those that would be
pplicable to other populations with known kid-
ey disease.
METHODS
Details of the design and methods of the Chronic Renal
mpairment in Birmingham (CRIB) Study have been de-
cribed previously9-11 and are summarized next.
ecruitment andEligibility Criteria
Between December 1997 and September 1999, individu-
ls with a serum creatinine level 1.5 mg/dL (but not
eceiving renal replacement therapy) attending a single large
K renal clinic in Birmingham were invited to take part in
he study. Approximately half the potentially eligible pa-
ients agreed to participate. There were no significant differ-
nces in age, sex, or kidney function between those who
greed and those who declined to participate. All partici-
ants provided written consent. Ethics approval was ob-
ained from the local research ethics committee.
aselineAssessment
At the initial interview, research nurses recorded medical
istory, current medication, clinical measurements, and a
2-lead electrocardiogram. Urine and nonfasting blood
amples were collected. Blood was separated using centrifu-
ation (3,000g at 4°C for 15 minutes) within 60 minutes and
tored at80°C.
In addition to the assays described previously,9-11 N-
erminal pro-brain natriuretic peptide (NT-pro-BNP) and
roponin T were measured using immunoassay methods on
oche automated analyzers (Roche, www.roche.com). A
igh troponin level was defined as 0.01 g/L.15 Symmet-
ic dimethylarginine, asymmetric dimethylarginine, and argi-
ine were assayed using stable isotope-dilution electrospray
ass spectrometry on a SCIEX API4000 analyzer (Applied
iosystems, www.appliedbiosystems.com). Creatinine was
easured using the Jaffé reaction, and eGFR was calculated
sing the 4-variable Modification of Diet in Renal Disease
MDRD) Study equation.16 Within- and between-batch coef-
cients of variation were10% for all assays. rollow-up
Participants were flagged for mortality at the Office for
ational Statistics (United Kingdom), which provided the
ate and cause of all deaths up to July 1, 2006. The
evelopment of ESRD (ie, initiation of maintenance dialysis
herapy or kidney transplant) was tracked through hospital
nd dialysis unit records to the end of 2007. For ESRD,
articipants who did not reach ESRD were censored at the
ate of death or the date at which they were last known to be
live and free of ESRD. For mortality, participants not
nown to have died by July 1, 2006, were censored on that
ate.
tatisticalMethods
Relevanceof IndividualCharacteristics toRisk
When appropriate, baseline characteristics were normal-
zed by applying a log transformation. Cox proportional
azards regression was used to estimate the average age- and
ex-adjusted relevance of each baseline characteristic to the
isks of ESRD and death (the small numbers of participants
ith missing data were assigned the mean or median value,
s appropriate). The magnitude of improvement in risk
rediction (compared with a model containing only age and
ex) was estimated by twice the change in the log-likelihood
tatistic (which, under the null hypothesis of no improve-
ent, gives a 2 statistic with 1 df). This test (the likelihood
atio test) provides not only a statistical test for improvement
n fit, but also a quantitative measure of the extent to which
he added term improves risk prediction.17 For continuous
xposures, log-linearity was assessed by testing the statisti-
al significance of including a quadratic term into the model
other tests for nonlinearity were not performed). To avoid
verfitting in the subsequent multivariable risk prediction
odels, only characteristics statistically significant at P 
.01 were considered further.
CombinedRelevanceof Several Characteristics toRisk
Characteristics found to be predictive of risk at the P 
.01 significance level in age- and sex-adjusted models were
ntered simultaneously (together with age and sex) into a
ingle model. A backwards elimination approach with a
trict P 0.01 inclusion criterion was then used to obtain an
ptimal subset of variables (a forwards selection approach
ielded the same results). Possible interactions between
ndividual factors were not considered, and no restrictions
ere placed on age and sex to remain in the final model. As
efore, the difference in twice the log-likelihood between 2
ested models (which gives a 2 statistic with df equal to the
ifference in the number of variables between models) was
sed to provide both an assessment of how well the reduced
et of factors predicted risk compared with the full set and a
ormal test for improvement in model fit. Relative risks
RRs; estimated using hazard ratios from the Cox model)
ssociated with differences in this final subset of characteris-
ics were calculated and used to derive absolute risk predic-
ion equations. To assess whether these average relative risks
een during the follow-up period might vary in magnitude
uring follow-up, the proportional hazards assumption of
he Cox model was tested by examination of the Schoenfeld
esiduals.18
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Landray et al1084ExternalValidation
External validation of the final prediction equations for
SRD and death was performed using information available
rom a separate cohort of 213 patients with stages 3-5 CKD
ecruited at a renal unit in East Kent between June 2003 and
une 2004. Participants were followed up for ESRD (mean,
.6 years) and death (mean, 3.3 years).19 Identical methods
ere used to measure NT-pro-BNP and troponin T, but
rinary albumin-creatinine ratio was not measured. External
alidation was performed by applying the frozen regression
oefficients from the final CRIB models to the individual
isk factors for each patient in the independent East Kent
ohort, yielding a predicted risk of ESRD and death for each
atient in this external cohort. For each outcome, the Hanley-
cNeil method20 was used to calculate the area under the
eceiver operating characteristic curve (ie, AUROC or C
tatistic, a measure of the discriminatory ability of the risk
odel) and its 95% confidence interval (CI). Calibration
as examined by separating individuals into 5 equal-sized
roups based on their predicted risk of each outcome and
omparing the observed annual event rates in these 5 groups
ith the predicted average annual event rates from the Cox
odel (using the baseline hazards seen in CRIB). Kaplan-
eier survival curves were also produced for each of 3
qual-sized predicted risk groups to illustrate the associa-
ions with observed risk over time.
RESULTS
aselineCharacteristics of StudyPopulation
The CRIB cohort included 382 participants
ith stages 3-5 CKD: 88 had stage 3 CKD (mean
GFR, 37.0 mL/min/1.73 m2), 178 had stage 4
KD (mean eGFR, 21.9 mL/min/1.73 m2), and
16 had stage 5 CKD (mean eGFR, 10.1 mL/min/
.73 m2. Baseline characteristics of the cohort
re listed in Table 1, and results of laboratory
ssays performed on baseline samples are listed
n Table 2.
isk of ESRDandAll-CauseMortality
During a mean of 4.1 years’ (1,571 person-
ears) follow-up for renal events, 190 partici-
ants reached ESRD (mean rate, 12.1% per an-
um [pa]; Table 3). In participants initially at
KD stages 3, 4, and 5, annual event rates of
SRD were 1.6%, 9.6%, and 58.2%, respec-
ively (between-group comparison, P  0.001;
ig 1). No patients with stage 3 CKD at baseline
equired dialysis or transplant within the first 4
ears of follow-up. In those with stage 4 CKD
nitially, median time to ESRD was about 5 years
onger than for those with stage 5 CKD (6 vs 1
ear, respectively; Fig 1). 4During a mean of 6.0 years’ (2,302 person-
ears) follow-up for mortality, 150 participants
ied (mean rate, 6.5% pa; Table 3). Of the 190
atients who reached ESRD, the subsequent mor-
ality rate was much greater in the 143 patients
ho received dialysis (71 subsequent deaths
8.3% pa]) than in the 47 patients who received a
idney transplant (2 subsequent deaths [0.5%
a]; P  0.001). Mortality rates were higher in
articipants with more advanced CKD at base-
ine: In those initially at CKD stages 3, 4, and 5,
nnual mortality rates were 3.9%, 6.3%, and
.2%, respectively (between-group comparison,
 0.001; Fig 1).
There were strong inverse log-linear associa-
ions between proportional differences in eGFR
nd risks of ESRD and death (Fig 2). This was
uch more marked for ESRD than for death.
ithin the range of eGFRs studied, each 30%
ower baseline eGFR (eg, 40 vs 28 mL/min/1.73
2) was associated with an approximately 3-fold
ncrease in risk of ESRD (RR, 3.02; 95% CI,
.65-3.43; P  0.001) and a 1.3-fold increase in
isk of death (RR, 1.30; 95% CI, 1.17-1.45; P 
.001). In this cohort, the risk of dying during
ollow-up exceeded that of developing ESRD for
hose with eGFR25 mL/min/1.73 m2 (Fig 2).
ndividual Risk-RelationsWith
SRDandMortality
Of the 44 baseline characteristics assessed, 20
howed strong (ie, P  0.01) associations with
SRD independently of age and sex (Table S1,
vailable as online supplementary material), of
hich 18 were still significant at P  0.001. For
ll-cause mortality, 19 baseline characteristics
howed strong associations independently of age
nd sex (Table S2), of which 12 were still signifi-
ant at P 0.001.
iskModels for ESRDandAll-CauseMortality
The baseline characteristics identified as asso-
iated with ESRD in age- and sex-adjusted anal-
ses (listed in Table S1), including age and sex,
ere considered for potential inclusion in an
SRD risk model. Using a backwards elimina-
ion selection process (see statistical methods), 4
ndependently informative predictors were iden-
ified: creatinine level, phosphate level, urinary
lbumin-creatinine ratio, and female sex (Table
). Together, these predicted risk to a degree
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Risk of ESRD and Death in CKD 1085imilar to all 22 candidate variables in combina-
ion (on dropping the other 18 factors, 2 for
odel fit decreased by only 26 [from 379.6 to
53.6], which, when tested against a 2 distribu-
ion with 18 df, gives P 0.10). Creatinine level
Table 1. Baseline Char
All
o. of people 382
ge (y) 61.5  14.3
GFRa (mL/min/1.73 m2) 21.8  10.7
en (%) 64.9
isease history (%)
Vascular disease 44.8
Diabetes mellitus 17.3
Left ventricular hypertrophyb 20.0
edication (%)
Any antihypertensive 83.0
Aspirin 27.2
Vitamin D 35.3
Calcium 21.7
Iron 25.1
Erythropoietin 9.4
Folic acid/B vitamins 12.0
moking status (%)
Never 36.6
Ex-smoker 50.8
Current 12.6
thnicity (%)
White 88.0
Black 5.8
Asian 6.3
hysical measurements
Weight (kg) 76.2  16.6
Height (m) 1.69  0.09
Waist-to-hip ratio 0.90  0.11
Body mass index (kg/m2) 26.6  5.0
SBP (mm Hg) 151.6  22.4
DBP (mm Hg) 83.9  11.8
Note: Values shown as number, percentage, or mean 
entricular hypertrophy, 4%; weight, 1%; waist-to-hip ratio,
actor for eGFR in mL/min/1.73 m2 to mL/s/1.73 m2,0.016
Abbreviations: CKD, chronic kidney disease; CRIB, C
ressure; eGFR, estimated glomerular filtration rate; K/DOQ
ion of Diet in Renal Disease; SBP, systolic blood pressure.
aCKD stage was as defined by the National Kidney Fou
L/min/1.73 m2; stage 4, eGFR of 15-30 mL/min/1.73 m2;
sing the 4-variable MDRD Study equation. Individuals rec
idney transplant) were excluded from the study.
bBased on an electrocardiogram.lone provided 80% of the information (21  208.5) available from knowledge of all 22 candi-
ate variables. In the final model, a 50% higher
aseline serum creatinine concentration (about 1
D [standard deviation]) was on average associ-
ted with an RR for ESRD of 3.25 (95% CI,
tics of the CRIB Cohort
CKD Stage at Baselinea
3 4 5
88 178 116
9.3  14.6 62.8  14.6 61.1  3.3
7.0  5.9 21.9  4.2 10.1  2.8
83.0 60.7 57.8
50.0 41.6 45.7
17.0 14.6 21.6
12.8 21.2 23.9
77.3 80.9 90.5
30.7 28.7 22.4
9.1 28.1 66.4
4.5 16.3 43.1
6.8 20.8 45.7
1.1 3.9 24.1
8.0 10.7 17.2
31.8 38.2 37.9
54.5 50.0 49.1
13.6 11.8 12.9
85.2 90.4 86.2
10.2 2.2 7.8
4.5 7.3 6.0
1.6  15.7 74.4  14.8 74.7  19.0
.71  0.08 1.68  0.09 1.68  0.09
.91  0.09 0.90  0.09 0.91  0.14
7.8  5.1 26.3  4.6 26.3  5.5
1.3  22.6 152.3  23.9 150.9  19.9
6.6  12.0 84.5  11.9 81.0  11.1
ard deviation for continuous measures. Missing data: left
dy mass index, 1%; and blood pressure, 1%. Conversion
Renal Impairment in Birmingham; DBP, diastolic blood
ey Disease Outcomes Quality Initiative; MDRD, Modifica-
’s K/DOQI Work Group in 2002: stage 3, eGFR of 30-60
age 5, eGFR 15 mL/min/1.73 m2. eGFR was calculated
renal replacement therapy at baseline (either dialysis or aacteris
5
3
8
1
0
2
15
8
stand
4%; bo
67.
hronic
I, Kidn
ndation
and st
eiving.69-3.92; P 0.001; Table 5) during follow-up.
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Landray et al1086owever, this RR decreased in magnitude with
ncreasing follow-up. The RR of ESRD for a
0% higher baseline creatinine level was about
wice as strong in the first 2 years of follow-up
by which time about half the ESRD events had
een observed: RR, 4.71 [95% CI 3.52-6.30])
han in subsequent years (RR, 2.43 [95% CI
.90-3.10]). In contrast, there was no evidence of
uch nonproportionality for the other predictors
Table 2. Baseline Labora
All
o. of people 382
idney function
Creatinine (mg/dL) 3.0 (2.2-4.6)
Cystatin C (mg/L) 3.0 (2.1-4.0)
UACR (mg/g) 460 (88-1,257
Symmetric dimethylarginine (mol/L) 1.38 (1.06-1.9
Urea (mg/dL) 114  54
Urate (mg/dL) 7.5  2.0
ardiac damage
NT-pro-BNP (ng/L) 530 (240-1,88
Increased TnT (0.01 ng/mL) 84 (22.4)
ndothelial function
ADMA (mol/L) 0.52 (0.45-0.5
Arginine (mg/dL) 3.1 (2.6-3.5)
vWF (IU/dL) 142 31
ipids
Total cholesterol (mg/dL) 217 49
HDL cholesterol (mg/dL) 49 16
nflammation & nutrition
C-Reactive protein (mg/L) 4.36 (1.36-9.5
Albumin (g/dL) 4.2 0.4
Fibrinogen (mg/dL) 348 79
IL-6 (ng/L) 3.9 (2.0-7.9)
TNF- (ng/L) 17.0 5.4
alcium and phosphate homeostasis
Calcium (mg/dL) 9.4 (9.1-9.7)
Phosphorus (mg/dL) 4.2 (3.7-4.9)
25 Hydroxyvitamin D3 (ng/mL) 17.8 (11.6-23.
1,25 Dihydroxyvitamin D3 (pg/mL) 23.9 (16.8-31.
Intact PTH (pg/mL) 134 (73-226)
Whole PTH (pg/mL) 74 (42-129)
Vitamins
Serum folate (ng/mL) 7.3 (5.2-11.5
Red cell folate (ng/mL) 214 (165-304
Vitamin B12 (pg/mL) 451 (333-591
Homocysteine (mg/L) 2.74 (2.14-3.4(Continuf ESRD. Given the overall average relevance of
aseline creatinine level to risk, the RR of ESRD
as about 50% higher for a 30% higher phos-
hate level (RR, 1.46; 95% CI, 1.21-1.77; P 
.001) and for a 5-fold higher urinary albumin-
reatinine ratio (RR, 1.51; 95% CI, 1.24-1.85; P 
.001), which represent differences of about 1 SD,
nd with female sex (RR, 1.54; 95% CI, 1.13-
.09; P  0.006; Table 5). Similar estimates for
alues in the CRIB Cohort
CKD Stage at Baselinea
3 4 5
88 178 116
2.0 (1.8-2.1) 2.9 (2.5-3.3) 5.7 (4.9-6.7)
1.8 (1.6-2.1) 2.8 (2.3-3.3) 4.4 (3.8-5.0)
250 (29-799) 339 (67-1,156) 896 (285-1,579)
0.95 (0.83-1.13) 1.36 (1.11-1.65) 2.25 (1.83-2.72)
65  21 104  35 168  49
7.0 1.8 7.7 1.9 7.7 2.2
222 (82-632) 463 (247-1,710) 1,376 (590-3,550)
13 (14.8) 30 (17.2) 41 (36.3)
0.49 (0.46-0.57) 0.52 (0.44-0.58) 0.55 (0.47-0.62)
3.0 (2.6-3.5) 3.1 (2.7-3.5) 3.1 (2.6-3.5)
134 31 142 32 148 30
221 42 222 55 207 42
49 15 50 16 46 16
3.78 (1.06-9.17) 4.93 (1.52-9.74) 4.05 (1.31-9.70)
4.2 0.4 4.2 0.5 4.1 0.4
338 77 344 85 363 72
3.6 (1.5-7.0) 3.8 (2.2-8.5) 4.4 (2.3-7.1)
14.9  4.9 16.7  5.1 19.1  5.4
9.4 (9.2-9.7) 9.3 (9.1-9.7) 9.3 (8.8-9.9)
3.7 (3.3-4.1) 4.1 (3.6-4.6) 5.3 (4.4-6.3)
20.7 (14.9-27.6) 17.4 (12.1-23.1) 15.4 (10.0-21.4)
30.5 (23.0-38.5) 23.9 (17.0-30.0) 18.7 (13.9-27.4)
77 (52-135) 144 (89-222) 194 (69-343)
46 (33-67) 80 (51-121) 102 (38-174)
6.6 (4.9-9.2) 7.2 (4.9-11.6) 8.0 (5.6-12.8)
207 (159-294) 218 (156-293) 223 (175-392)
435 (335-587) 451 (334-571) 457 (327-637)
2.28 (1.73-2.80) 2.81 (2.27-3.41) 3.24 (2.45-4.33)tory V
)
2)
2)
8)
4)
3)
6)
)
)
)
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Risk of ESRD and Death in CKD 1087hese other factors were obtained when the RR
ssociated with creatinine level was specifically
odeled as a time-dependent covariate.
For mortality, 4 baseline characteristics (of the
1 candidate exposures, including age and sex;
ee Table S2) were identified as independent
Table 2 (Cont’d). Baseline La
All
heologic markers
Soluble P selectin (g/L) 55.0 (45.0-75.
Hemoglobin (g/dL) 12.1 2.0
Note: Values expressed as mean standard deviation, me
DL cholesterol (20%), UACR (19%), intact PTH (15%), red c
brinogen (11%), and all other markers (10% and mostly5%
ACR in mg/g to mg/mmoL, 0.115; urea in mg/dL to mmol/
mol/L,57.4; cholesterol in mg/dL to mmol/L,0.02586; fibri
hosphorus in mg/dL to mmol/L, 0.3232; 25 hydroxyvitamin D
mol/L, 2.6; PTH in pg/mL to pmol/L, 0.1073; folate in ng/
omocysteine in mg/L tomol/L,7.397. No conversion necess
Abbreviations: ADMA, asymmetric dimethylarginine; CK
irmingham; eGFR, estimated glomerular filtration rate; HD
uality Initiative; IL-6, interleukin 6; MDRD, Modification
atriuretic peptide; PTH, parathyroid hormone; TNF-, tum
reatinine ratio; vWF, von Willebrand factor.
aCKD stage was as defined by the National Kidney Fou
L/min/1.73 m2; stage 4, eGFR of 15-30 mL/min/1.73 m2;
sing the 4-variable MDRD Study equation. Individuals rec
idney transplant) were excluded from the study.
Table 3. Incidence of ESR
All
o. of people 382
SRD
Total person-years of follow-up 1,571
ESRD 190 (12.1%/y)
ortality
Total person-years of follow-up 2,302
Vascular 74
Nonvascular 71
Unknown 5
All-cause mortality 150 (6.5%/y)
Abbreviations: CKD, chronic kidney disease; CRIB, Chro
ar filtration rate; ESRD, end-stage renal disease; K/DOQI,
f Diet in Renal Disease.
aCKD stage was as defined by the National Kidney Fou
L/min/1.73 m2; stage 4, eGFR of 15-30 mL/min/1.73 m2;
sing the 4-variable MDRD Study equation. Individuals rec
idney transplant) were excluded from the study.redictors: NT-pro-BNP level, age, current ciga-
ette smoking, and increased troponin T level (2
or combined model fit  138.8 compared with
60.8 if all 21 factors were included; a difference
f 22, which, when tested against a 2 distribu-
ion with 17 df, gives P 0.2; Table 4). Of these,
ry Values in the CRIB Cohort
CKD Stage at Baselinea
3 4 5
53.0 (45.0-70.5) 55.5 (44.5-78.0) 60.0 (48.0-75.0)
13.6  1.8 12.1  1.8 10.8  1.6
5th-75th percentiles), or number (percentage). Missing data:
te (13%), 1,25 dihydroxyvitamin D3 (12%), whole PTH (11%),
version factors for units: creatinine in mg/dL to mol/L,88.4;
667; urate in mg/dL to mol/L, 59.48; arginine in mg/dL to
in mg/dL to g/L,0.01; calcium in mg/dL to mmol/L,0.2495;
/mL to nmol/L, 2.496; 1,25 dihydroxyvitamin D3 in pg/mL to
mol/L, 2.266; vitamin B12 in pg/mL to pmol/L, 0.738; and
troponin T in ng/mL andg/L.
onic kidney disease; CRIB, Chronic Renal Impairment in
h-density lipoprotein; K/DOQI, Kidney Disease Outcomes
et in Renal Disease; NT-pro-BNP, N-terminal pro-brain
crosis factor ; TnT, troponin T; UACR, urinary albumin-
’s K/DOQI Work Group in 2002: stage 3, eGFR of 30-60
age 5, eGFR 15 mL/min/1.73 m2. eGFR was calculated
renal replacement therapy at baseline (either dialysis or a
Death in the CRIB Cohort
CKD Stage at Baselinea
III IV V
88 178 116
560 837 173
9 (1.6%/y) 80 (9.6%/y) 101 (58.2%/y)
590 1,072 640
10 39 25
11 27 33
2 2 1
23 (3.9%/y) 68 (6.3%/y) 59 (9.2%/y)
nal Impairment in Birmingham; eGFR, estimated glomeru-
Disease Outcomes Quality Initiative; MDRD, Modification
’s K/DOQI Work Group in 2002: stage 3, eGFR of 30-60
age 5, eGFR 15 mL/min/1.73 m2. eGFR was calculated
renal replacement therapy at baseline (either dialysis or aborato
0)
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Landray et al1088ge and NT-pro-BNP level were related most
trongly to risk. In the final model, the risk of
eath was approximately doubled for each 15
ears of older age (RR, 1.95; 95% CI, 1.54-2.45;
 0.001), each 5-fold higher NT-pro-BNP
Figure 1. Time to end-stage renal disease (ESRD) an
tudy, by initial chronic kidney disease (CKD) stage. The P
cross all 3 baseline CKD groups. CKD stage was as defin
utcomes Quality Initiative) Work Group in 2002: stage 3,
2; stage 4, eGFR of 15-30 mL/min/1.73 m2; and stage
-variable Modification of Diet in Renal Disease (MDRD) S
aseline (either dialysis or a kidney transplant) were exclud
Figure 2. Age- and sex-adjusted relative risk (RR) of e
enal Impairment in Birmingham) Study by baseline es
-variable Modification of Diet in Renal Disease [MDRD] St
logarithmic scale. The points in the right hand panel have
re comparable with the absolute ESRD rates represented
he level of eGFR above which, in the CRIB cohort, the risk of de
onfidence interval.evel (RR, 1.72; 95% CI, 1.41-2.12; P  0.001),
urrent cigarette smoking (RR, 2.36; 95% CI,
.56-3.59; P  0.001), and a positive troponin T
esult (RR, 1.83; 95% CI, 1.26-2.66; P  0.001;
able 5). There was no evidence that these RRs
in the Chronic Renal Impairment in Birmingham (CRIB)
r the log-rank test corresponds to the test of equal survival
e National Kidney Foundation’s K/DOQI (Kidney Disease
ted glomerular filtration rate (eGFR) of 30-60 mL/min/1.73
R 15 mL/min/1.73 m2. eGFR was calculated using the
uation. Individuals receiving renal replacement therapy at
the study.
ge renal disease (ESRD) and death in the CRIB (Chronic
d glomerular filtration rate (eGFR; calculated using the
ation). Both the horizontal and vertical axes are shown on
djusted so that the absolute mortality rates they represent
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Risk of ESRD and Death in CKD 1089aried in magnitude with increasing duration of
ollow-up (global test for nonproportionality, P 
.2).
These independently informative predictors
ere used to develop risk equations for the
rediction of ESRD (based on creatinine level,
hosphate level, urinary albumin-creatinine ra-
io, and sex) and death (based on NT-pro-BNP
evel, age, cigarette smoking, and troponin T
evel). These equations have been incorporated
n an open-access risk calculator, available at
ww.ctsu.ox.ac.uk/cribcalculator.
xternal Validationof Risk Prediction Equations
Within the East Kent cohort of 213 patients
ith CKD stages 3-5 (not on renal replacement
herapy), baseline characteristics were broadly
imilar to those in the CRIB Study (see Table
Table 4. Joint Relevance of Baseline Chara
Risk Model
Predict
nitial and final selected risk model
Age, sex and all factors listed in Table S1
ln creatinine, ln phosphate, ln UACR, and sex
ncremental relevance of factors in final model
ln creatinine
ln creatinine and ln phosphate
ln creatinine, ln phosphate, and ln UACR
ln creatinine, ln phosphate, ln UACR, and sex
Prediction of
nitial and final selected risk model
Age, sex and all factors listed in Table S2
ln NT-pro-BNP, age, current smoking, and increased TnT
ncremental relevance of factors in final model
ln NT-pro-BNP
ln NT-pro-BNP and age
ln NT-pro-BNP, age, and current smoking
ln NT-pro-BNP, age, current smoking, and increased TnT
Abbreviations: CI, confidence interval; CRIB, Chronic
umber of terms in model); ESRD, end-stage renal dis
atriuretic peptide; TnT, troponin T; UACR, urinary albumin
aThe statistical improvement in model fit between any
etween 2 statistics. For example, for ESRD, the model w
he model containing just log creatinine, log phosphate, lo
ields P  0.10 when tested against a 2 distribution with
odels]). In comparison, adding log phosphate to a mo
rediction for ESRD (because a 2 statistic of 329.8308.5
df).3). Prediction equations derived from the CRIB Eohort were assessed independently for discrimi-
ation and calibration in the East Kent cohort
because urinary albumin-creatinine ratio was
ot measured in the East Kent cohort, all partici-
ants were assigned an arbitrary value of 350
g/g). Even without knowledge of ACR, there
as clear separation in risk over time between
eople at low, medium, and high risk of each
utcome (Fig 3A), and the AUROC (the C statis-
ic) was very good for both ESRD (0.91; 95% CI,
.87-0.96) and death (0.82; 95% CI, 0.75-0.89;
ig 3B). When participants in the East Kent
ohort were separated into 5 groups based on
redicted risks of each outcome, observed an-
ual event rates were systematically lower than
redicted rates for ESRD, but reasonably well
atched for mortality (Fig 3C). Virtually identi-
al estimates of discrimination and calibration of
ics to ESRD and Death in the CRIB Cohort
f
Improvement in Fit Compared
With No Markersa C Statistic (95% CI)
ESRD
2 379.6 0.903 (0.872-0.935)
4 353.6 0.873 (0.836-0.909)
1 308.5 0.843 (0.804-0.883)
2 329.8 0.855 (0.817-0.893)
3 346.1 0.865 (0.828-0.903)
4 353.6 0.873 (0.836-0.909)
use Mortality
1 160.8 0.855 (0.813-0.896)
4 138.8 0.820 (0.774-0.866)
1 76.1 0.736 (0.684-0.789)
2 114.6 0.787 (0.739-0.836)
3 129.1 0.811 (0.764-0.857)
4 138.8 0.820 (0.774-0.866)
Impairment in Birmingham; df, degrees of freedom (ie,
ln, natural logarithm; NT-pro-BNP, N-terminal pro-brain
nine ratio.
ted” models can be evaluated by comparing differences
2 markers is not significantly better at predicting risk than
R, and sex (because a 2 statistic of 379.6353.6  26
[the difference in the number of markers in the 2 nested
t contains only log creatinine significantly improves risk
yields P 0.001 when tested against a 2 distribution withcterist
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ion of
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Landray et al1090ions that allowed the RR for creatinine level to
ary during follow-up were used.
DISCUSSION
This study confirms the high risks of progres-
ion to ESRD and death in patients with stages
-5 CKD (particularly those with eGFR 45
L/min/1.73 m2) who had been referred to a
pecialist nephrology center, but were not receiv-
ng dialysis. The risks of each of these outcomes
ere closely associated with baseline kidney
unction throughout the range studied, but this
ssociation was much stronger for ESRD than
or death. Within this cohort, the absolute risk of
SRD was greater than the risk of death for
ndividuals with eGFR approximately 25 mL/
in/1.73 m2 (ie, CKD stage 4 or 5), whereas the
onverse was true for those with better levels of
aseline kidney function. However, the precise
hreshold at which this change in prognosis oc-
urs is likely to vary both between populations
nd over time, largely depending on the underly-
ng absolute risk of death.5,21,22
The finding that more advanced renal impair-
ent is associated with increased risks of death
nd in particular ESRD is likely to be caused in
art by the “horse-racing effect,”23 a term used to
escribe the observation that the absolute value
Table 5. Adjusted Relative Risks
Model Baseline Measurement
SRD Creatinine
Phosphate
ACR
Sex
eath Age
NT-pro-BNP
Cigarette smoking
TnT
Abbreviations: ACR, albumin-creatinine ratio; CI, confid
SRD, end-stage renal disease; NT-pro-BNP, N-termina
eviation; TnT, troponin T.
aComparisons correspond to about 1-SD differences in a
og ACR, and log NT-pro-BNP (for comparability between c
bFor creatinine, associations with ESRD risk were approx
ater years. Per 50% higher baseline creatinine concentra
ears of follow-up and 2.43 (95% CI, 1.90-3.10) subseque
aseline creatinine level during follow-up.
cIncreased defined as0.01 ng/mL.f a risk exposure tends to correlate positively pith the rate of change in that exposure. Thus,
ecause baseline creatinine concentration is likely
o correlate highly with the rate of decrease in an
ndividual’s kidney function, the excess risks
bserved in individuals for whom kidney func-
ion was worst at a single “baseline” assessment
ay occur because these people were experienc-
ng progression most rapidly. (This also could
xplain why the RR of ESRD associated with
ifferences in baseline creatinine level was higher
n earlier years of follow-up than in the later
ears.) Nonetheless, this still does not diminish
he utility of such a measurement as a simple
rognostic tool.
The CRIB cohort is well characterized and
ncludes a very large range of potential risk
arkers recorded at baseline. The principal deter-
inant of the probability of progression to ESRD
s kidney function. The final model includes 3
arkers of kidney damage (serum creatinine
evel, serum phosphate level, and urinary albu-
in-creatinine ratio) plus sex, which may reflect
hat GFR is lower in women than men for a given
reatinine level (and therefore the RR of ESRD
or female sex is 1). Age did not remain in the
nal model because much of the predictive asso-
iation between age and ESRD was provided by
reatinine level alone. This is in contrast to other
D and Death in the CRIB Cohort
Comparison RR (95% CI)
50% higher levela 3.25 (2.69-3.92)b
30% higher levela 1.46 (1.21-1.77)
5-fold higher levela 1.51 (1.24-1.85)
ale vs male 1.54 (1.13-2.09)
15 y oldera 1.95 (1.54-2.45)
5-fold higher levela 1.72 (1.41-2.12)
ent vs not current 2.36 (1.56-3.59)
ased vs not increasedc 1.83 (1.26-2.66)
terval; CRIB, Chronic Renal Impairment in Birmingham;
rain natriuretic peptide; RR, relative risk; SD, standard
d about 1-SD differences in log creatinine, log phosphate,
ristics).
twice as strong in the earlier years of follow-up than in the
e RR of ESRD was 4.71 (95% CI, 3.52-6.30) in the first 2
e RR shown therefore is the average RR associated withfor ESR
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Risk of ESRD and Death in CKD 1091Figure 3. External valida-
ion of the CRIB (Chronic Re-
al Impairment in Birmingham)
isk score equations in the East
ent cohort: Kaplan-Meier sur-
ival curves by third of the pre-
icted risk distributions (top
anels); receiver operating
haracteristic curves (middle
anels); and observed versus
redicted annual event rates
bottom panels). The P value
or the log-rank test corresponds
o the test of equal survival
cross all 3 predicted risk
roups. *Urinary albumin-creati-
ine ratio was not available in
he East Kent cohort; therefore,
he measures of discrimination
nd calibration shown reflect the
bility of the other factors (sex,
reatinine level, and phosphate
evel) to predict end-stage renal
isease (ESRD) risk. Abbrevia-
ions: AUROC, area under the
eceiver operating characteristic
urve (C statistic); CI, confi-
ence interval; NT-pro-BNP, N-
erminal pro-brain natriuretic
eptide.
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Landray et al1092emained significantly related to risk indepen-
ently of creatinine level.24,25 In our study, creat-
nine level alone provided about 80% of the
redictive information for ESRD that was pro-
ided by including a full array of 21 different
actors (age, sex, and 19 other factors that were
trongly predictive of ESRD in age- and sex-
djusted models), indicating the importance of
he current level of kidney function in predicting
he risk of progression to ESRD. Previous stud-
es that have developed risk scores for kidney
isease progression have also found that markers
f kidney function (creatinine level, eGFR, and
roteinuria) or factors highly correlated with
idney function (such as blood pressure, diabe-
es, anemia, and serum phosphate level) are
articularly informative.26-30
In contrast, the probability of dying depends
hiefly on markers of morbidity (ie, age, NT-pro-
NP level, troponin T level, and cigarette smok-
ng). Increased plasma concentrations of NT-pro-
NP or troponin T (assays commonly available in
outine clinical laboratories) provide quantitative
stimates of the severity of cardiovascular disease
n an individual: NT-pro-BNP level may be associ-
ted with left ventricular hypertrophy and dysfunc-
ion, fluid overload, and ischemia, although it also
ay indicate more severe decreases in GFR,31 and
roponin T most likely reflects a combination of
yocardial necrosis, hypertrophy, and dysfunc-
ion.32 Increased NT-pro-BNP level is a powerful
redictor of mortality in individuals with vascular
isease, diabetes, or heart failure, in the unselected
eneral population, and in patients with CKD.31,33-36
etectable levels of troponin T were predictive of
ll-cause and cardiac mortality in studies of elderly
eople in the general population37 and patients
ith moderate to severe CKD both before and after
he need for dialysis therapy.15,31,38-39
Many candidate factors were measured in this
tudy, but were not associated independently
ith renal progression or death in age- and
ex-adjusted analyses. In patients with more se-
ere renal impairment, relationships between ex-
osures and risk of clinically important events
re likely to be substantially confounded by
ither disease (eg, cholesterol level) or treatment
eg, blood pressure).14 As a consequence, predic-
ion equations developed in the general popula-
ion (largely without significant kidney dysfunc-
ion) perform very poorly in the CKD aopulation.13 Many of the exposures measured
orrelated closely, particularly with serum creati-
ine level (Table S4), and thus do not appear in
he final risk score models. Of course, these
odels provide no information about causality
or lack of it) and are intended to be predictive
ather than explanatory.
Results of the external validation show excel-
ent discrimination for ESRD and all-cause mor-
ality (AUROCs, 0.91 and 0.82, respectively).
ad urinary albumin-creatinine ratio been avail-
ble, it is likely that discrimination would have
een even better. Levin et al40 recently have
eported risk equations for ESRD and death.
nfortunately, many of the baseline factors re-
uired for these equations were not available in
he East Kent cohort. However, within the CRIB
ohort, these equations yielded smaller C statis-
ics of 0.65 (95% CI, 0.58-0.72) for ESRD and
.73 (95% CI, 0.67-0.79) for death. When the
RIB mortality risk prediction equation was
pplied to the East Kent cohort for the outcome
f death before ESRD, the C statistic (0.79; 95%
I, 0.71-0.86) was similar to that seen for all
eaths. However, the study was too small to
llow risk equations to be developed separately
or specific causes of death, whereas a lack of
ollow-up for nonfatal cardiovascular events pre-
luded further analyses of this type.
This study confirms the log-linear association
etween RR of both ESRD and death with propor-
ional decreases in eGFR. Using simple currently
vailable laboratory measures of kidney and car-
iac function plus age, sex, and history of ciga-
ette smoking, it is possible to identify patients
ith CKD at greatest absolute risk of these
linical outcomes within the next few years. We
ave developed an open-access web application
hat illustrates how these equations might be
sed in routine clinical practice, available at
ww.ctsu.ox.ac.uk/cribcalculator.
The results are most directly relevant to pa-
ients with eGFR 45 mL/min/1.73 m2, and
urther work is required to assess the perfor-
ance of these equations in larger cohorts and
ndividuals with less severe decreases in kidney
unction.
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Table S1: Relevance of baseline characteristics to ESRD
n the CRIB cohort, given age and sex.
Table S2: Relevance of baseline characteristics to death in
he CRIB cohort, given age and sex.
Table S3: Baseline characteristics and outcome in the East
ent validation cohort.
Table S4: Age- and sex-adjusted correlations between
hose continuous markers found to predict either ESRD or
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